Piper Jaffray has an Overweight rating on Exelixis, Inc. EXEL and a $9 price target on the stock.
In a research report sent to clients, Piper Jaffray writes, "Today at the EORTC meeting in Berlin, Exelixis presented 6 posters on the on-going Phase II randomized discontinuation trial (RDT) of XL184 in multiple
cancer types. We were also impressed by the activity seen in ovarian cancer with a 12-week disease control rate of 64%. We believe XL184 is the path forward for Exelixis with a potential O.U.S. partnership and first market approval by 2012."
Shares of EXEL gained 33 cents yesterday to close at $4.72, a gain of 7.5%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareLife Sciences Tools & ServicesPiper Jaffray
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in